PapersPMID:9892253
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
What moved
1 findingHow to read these marks →- Decreases PANSS negative subscale score
very limited
“Glycine administration resulted in (1) a significant (P<.001) 30%+/-16% reduction in negative symptoms, as measured by the PANSS, and (2) a significant (P<.001) 30%+/-18% improvement in the BPRS total scores.”
- Study
- crossover
- Dose studied
- 0.8 g/kg per day glycine added to ongoing antipsychotic medication
- Population
- Twenty-two treatment-resistant schizophrenic patients with enduring negative symptoms, glycine added to ongoing antipsychotic medication in a double-blind placebo-controlled crossover
Study record
- Design
- crossover trial
- Species
- human
- Population
- treatment-resistant schizophrenic patients with enduring negative symptoms on ongoing antipsychotic medication
- Participants
- 22
- Comparator
- placebo
- Duration
- 42 days
- Endpoints measured
- 6
- Declined
- this platform holds no node for the endpoint
glycine